AI Article Synopsis
- Hypogonadal men typically have smaller prostate volumes and lower PSA levels compared to men with normal testosterone levels.
- Prostate cancer in hypogonadal men tends to be more aggressive, highlighting the need for better diagnostic tests due to PSA's lack of specificity.
- After starting testosterone replacement therapy, it's important to monitor PSA levels regularly, especially since an increase of over 0.5 ng/mL within 3-6 months indicates the need for further investigation.
Article Abstract
Hypogonadal men have lower prostate volumes and serum prostate-specific antigen (PSA) levels than age-matched controls. When present, prostate cancer in hypogonadal men is more aggressive than in eugonadal men, and given the lack of specificity of PSA for diagnosing prostate cancer, a more accurate test would be desirable in hypogonadal men. Once testosterone-replacement therapy is started in hypogonadal men, PSA levels should be measured regularly; however, there is often an initial rise 3-6 months after starting treatment. A rise of >0.5 ng/mL within this time requires further investigation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1464-410X.2006.06191.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infidelity in Men with Erectile Dysfunction and Its Association with the Severity of the Condition: A Comparative Analysis Across Six Ibero-american Countries.
J Sex Marital Ther
January 2025
Clinical Research Department, Elexial Research, Urology, Boston Medical Group, Bogotá, Colombia.
In this study, data from 7,440 patients from six Ibero-American countries were analyzed, focusing on men who consulted for erectile dysfunction (ED). Participants were queried about infidelity in their relationships. Results showed a negative correlation between infidelity and the severity of ED, suggesting that the likelihood of infidelity decreases as the severity of ED increases.
View Article and Find Full Text PDFBackground: Differential diagnosis of hypogonadotropic hypogonadism (HH) and constitutional delay of puberty (CDP) is extremely important since with the latter puberty begins and completes without any medical intervention and in the case of HH puberty does not occur or is incomplete. Failure to start treatment on time leads to medical and psychosocial maladjustment of the patient.
Aim: Development of a method for differential diagnosis of hypogonadotropic hypogonadism and constitutional delay of puberty in boys 13.
Development of a transdermal gel for reversible male contraception.
Contraception
January 2025
Division of Endocrinology, Department of Medicine, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California; Clinical and Translational Science Institute, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, California.
While there are several easy-to-use reversible female contraceptives, little is available for men. Introduction of novel, cost-effective male contraceptives could have important downstream global health and economic benefits. Currently, nearly half of all pregnancies globally are unintended, with many resulting in unsafe abortions, a significant burden for women and families in many countries.
View Article and Find Full Text PDFPRDM16 Enhances Osteoblastogenic RUNX2 via Canonical WNT10b/β-CATENIN Pathway in Testosterone-Treated Hypogonadal Men.
Biomolecules
January 2025
Division of Endocrinology Diabetes and Metabolism, Baylor College of Medicine, Houston, TX 77030, USA.
We previously reported that mediated the improvement in body composition in testosterone (T)-treated hypogonadal men by shifting adipogenesis to myogenesis. Previous preclinical studies suggest that regulates , an important osteoblastic transcription factor, expression and activity. However, the changes in , and other genes/proteins involved in osteoblastogenesis with T therapy in hypogonadal men are unexplored.
View Article and Find Full Text PDFBackground: An estimated 17% of all couples worldwide are involuntarily childless (infertile). The clinically identifiable causes of infertility can be found in the male or female partner or in both. The molecular pathophysiology of infertility still remains unclear in many cases but is increasingly being revealed by genetic analyses.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!